Skip to main content

Find Clinical Trials

Home
Conditions
Hematologic Malignancies

Clinical trial condition

Hematologic Malignancies

Explore clinical trials studying Hematologic Malignancies. Study availability and eligibility vary by location and protocol.

136 public trials 31 recruiting studies

Refine in advanced search Browse all conditions

Hematologic Malignancies trial results

Completed

Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

NCT00369226

Conditions: Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +3 more
Locations: Brigham and Women's Hospital Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Completed

Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor

NCT00993486

Conditions: Graft vs Host Disease, Hematologic Diseases, Hematologic Malignancies, +5 more
Locations: Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada

View Trial Details

Completed

Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets

NCT01687231

Conditions: Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +3 more
Locations: Duke University Medical Center Durham, North Carolina, United States

View Trial Details

Completed

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

NCT00521859

Conditions: Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +12 more
Locations: UT MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

A Phase I Dose Escalation Study of Oral SB939 Administered Alone or With Azacitidine

NCT00741234

Conditions: Bone Marrow Diseases, Hematologic Diseases, Hematologic Malignancies, +7 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

University of Wisconsin-Madison Madison, Wisconsin, United States

National University Hospital Singapore

National Cancer Center Singapore

View Trial Details

Completed

Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies

NCT00208923

Conditions: Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +3 more
Locations: Emory Universtiy Winship Cancer Institute Atlanta, Georgia, United States

View Trial Details

Completed

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

NCT00881946

Conditions: Blood Protein Disorders, Bone Marrow Diseases, Cardiovascular Diseases, +33 more
Locations: Prince of Wales Hospital Sydney, New South Wales, Australia

The Alfred Hospital Melbourne, Victoria, Australia

Princess Margaret Hospital Toronto, Ontario, Canada

Seoul National University Hospital Seoul, South Korea

View Trial Details

Completed

Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation

NCT00146614

Conditions: Graft Versus Host Disease, Graft vs Host Disease, Hematologic Diseases, +6 more
Locations: Beth Isreal Deaconess Medical Center Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

Massachusetts General Hospital Boston, Massachusetts, United States

View Trial Details

Completed

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

NCT00506857

Conditions: Hematologic Diseases, Hematologic Malignancies, Hematologic Neoplasms, +11 more
Locations: UT MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Completed

Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation

NCT00144703

Conditions: Acute Lymphoblastic Leukemia, Bone Marrow Diseases, Graft vs Host Disease, +23 more
Locations: Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details